A Risk-Adapted Approach to Breast Radiation Using Targeted Intraoperative Radiotherapy (TARGIT)

  • Jayant S. Vaidya
  • Jeffrey S. Tobias
  • Frederik Wenz
  • Samuele Massarut
  • Max Bulsara
  • Christobel Saunders
  • Henrik Flyger
  • Michael Alvarado
  • Wolfgang Eiermann
  • Tammy Corica
  • David Joseph
  • Michael Baum
Chapter
First Online:

Abstract

Whole-organ detailed three-dimensional pathological analysis of mastectomy specimens vis-à-vis the results of breast-conserving surgery trials demonstrates a remarkable phenomenon: in addition to the main tumor, the mastectomy specimen reveals often multiple foci of cancer distributed widely in the breast volume. This is in contrast with the location of a local recurrence, which mostly occurs in the area around the original tumor – thus, it makes sense to focus radiation only around the original tumor. Based on this insight, the targeted intraoperative radiotherapy technique and the device to deliver it were developed in the late 1990s, the first case treated at the Middlesex Hospital, University College London, UK, on 2 July 1998. Pilot studies confirmed feasibility and safety, and in March 2000, the TARGIT-A randomized trial was launched.

Keywords

Local Recurrence Breast Cancer Mortality Ipsilateral Breast Tumor Recurrence Axillary Recurrence Wound Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996;274(5295):2057–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Belletti B, Vaidya JS, D’Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovo MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res (An Official Journal of the American Association for Cancer Research). 2008;14(5):1325–32.CrossRefGoogle Scholar
  3. 3.
    Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M, Hilaris B, Saunders C, Williams NR, Brew-Graves C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Sutterlin M, Bulsara M, Joseph D. Long-term results of targeted intraoperative radiotherapy (TARGIT) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011;81(4):1091–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.CrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355(9217):1757–70.CrossRefGoogle Scholar
  7. 7.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333(22):1444–55.CrossRefGoogle Scholar
  8. 8.
    Halsted WS. The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Hospital Reports. 1894;4:297–350.Google Scholar
  9. 9.
    Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol. 2005;23(24):5526–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92(3):269–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Sedlmayer F, Rahim HB, Kogelnik HD, Menzel C, Merz F, Deutschmann H, Kranzinger M. Quality assurance in breast cancer brachytherapy: geographic miss in the interstitial boost treatment of the tumor bed. Int J Radiat Oncol Biol Phys. 1996;34(5):1133–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Machtay M, Lanciano R, Hoffman J, Hanks GE. Inaccuracies in using the lumpectomy scar for planning electron boosts in primary breast carcinoma. Int J Radiat Oncol Biol Phys. 1994;30(1):43–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol. 2003;48(2):139–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Mikeljevic JS, Haward R, Johnston C, Crellin A, Dodwell D, Jones A, Pisani P, Forman D. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer. 2004;90(7):1343–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Massarut S, Baldassare G, Belleti B, Reccanello S, D’Andrea S, Ezio C, Perin T, Roncadin M, Vaidya JS. Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid. J Clin Oncol. 2006;24(18S):10611.Google Scholar
  16. 16.
    Baldassarre G, Belleti B, Vaidya JS, D'Andrea S, Roncadin M, Perin T, Trova MG, Candiani E, Veronesi A, Colombatti A, Massarut S. Intraoperative radiotherapy (IORT) impairs surgical wound-stimulated breast cancer cell invasion. J Clin Oncol. 2007;25(18S):21139.Google Scholar
  17. 17.
    Rutqvist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer. 1990;61(6):866–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    O’Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed). 1988;296(6624):741–43.Google Scholar
  19. 19.
    Nakamura J, Savinov A, Lu Q, Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology. 1996;137(12):5589–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology. 1996;137(7):3061–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer. 2000;88(5):1091–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations [see comments]. J Clin Oncol. 1999;17(10):3017–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996;74(5):820–4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Baum M, Vaidya JS. Molecular staging of cancer [letter; comment]. Lancet. 1997;350(9082):962.CrossRefPubMedGoogle Scholar
  25. 25.
    Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer. 1987;56(6):814–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345(19):1378–87.CrossRefPubMedGoogle Scholar
  27. 27.
    Clark RM, Wilkinson RH, Mahoney LJ, Reid JG, MacDonald WD. Breast cancer: a 21 year experience with conservative surgery and radiation. Int J Radiat Oncol Biol Phys. 1982;8(6):967–79.CrossRefPubMedGoogle Scholar
  28. 28.
    McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg. 1993;80(8):1005–07.CrossRefPubMedGoogle Scholar
  29. 29.
    Clarke DH, Martinez AA. Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: a review article for surgeons, pathologists, and radiation and medical oncologists [see comments]. J Clin Oncol. 1992;10(3):474–83.CrossRefPubMedGoogle Scholar
  30. 30.
    Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333(22):1456–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH, Mahoney LJ. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88(22):1659–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, Adami HO. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial [see comments]. J Clin Oncol. 1999;17(8):2326–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, Smith DC, George WD. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group [see comments]. Lancet. 1996;348(9029):708–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, Rilke F, Sacchini V, Saccozzi R, Savio T. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast [see comments]. N Engl J Med. 1993;328(22):1587–91.CrossRefPubMedGoogle Scholar
  35. 35.
    Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, Sainsbury R, Massarut S, Taylor I, Hilaris B. Intraoperative radiotherapy for breast cancer. Lancet Oncol. 2004;5(3):165–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pelegrin A. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7(1):R156–63.CrossRefPubMedGoogle Scholar
  37. 37.
    Vaidya JS, Baum M, Tobias JS, D’Souza DP, Naidu SV, Morgan S, Metaxas M, Harte KJ, Sliski AP, Thomson E. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2001;12(8):1075–80.CrossRefGoogle Scholar
  38. 38.
    Vaidya JS, Baum M, Tobias JS, Houghton J. Targeted intraoperative radiothearpy (TARGIT)- trial protocol. Lancet. 1999. http://www.thelancet.com/protocol-reviews/99PRT-47.
  39. 39.
    Vaidya JS, Baum M, Tobias JS, Morgan S, D'Souza D. The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol (The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology). 2002;28(4):447–54.Google Scholar
  40. 40.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT Trialists’ Group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603–13.CrossRefPubMedGoogle Scholar
  41. 41.
    Vaidya JS, Walton L, Dewar J. Single dose targeted intraoperative radiotherapy (TARGIT) for breast cancer can be delivered as a second procedure under local anaesthetic. World J Surg Oncol. 2006;4:2.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sutterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91–102.CrossRefPubMedGoogle Scholar
  43. 43.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias J, Baum M. Pride, Prejudice, or Science – attitudes towards the results of the TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2015;92(3):491–7.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vaidya JS, Bulsara M, Wenz F. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med. 2013;368(26):2526–7.PubMedGoogle Scholar
  45. 45.
    Corica T, Nowak A, Saunders C, Bulsara M, Joseph D. Patient preferences for adjuvant radiotherapy in early breast cancer – an Australian Sub-study of the International TARGIT Trial. Eur J Cancer. 2012;48(Suppl 1):S187: Abstract 482.Google Scholar
  46. 46.
    Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M, Hilaris B, Saunders C, Williams N, Brew-Graves C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Sutterlin M, Bulsara M, Joseph D. Long term results of targeted intraoperative radiotherapy (Targit) boost during breast conserving surgery. Int J Radiat Oncol Biol Phys. 2011;81(4):7.Google Scholar
  47. 47.
    Vaidya JS, Baum M, Tobias JS, Massarut S, Wenz F, Murphy O, Hilaris B, Houghton J, Saunders C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Melchaert F, Keshtgar M, Sainsbury R, Douek M, Harrison E, Thompson A, Joseph D. Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. Int J Radiat Oncol Biol Phys. 2006;66(5):1335–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Jayant S. Vaidya
    • 1
  • Jeffrey S. Tobias
    • 2
  • Frederik Wenz
    • 3
  • Samuele Massarut
    • 4
  • Max Bulsara
    • 5
  • Christobel Saunders
    • 6
  • Henrik Flyger
    • 7
  • Michael Alvarado
    • 8
  • Wolfgang Eiermann
    • 9
  • Tammy Corica
    • 10
  • David Joseph
    • 10
  • Michael Baum
    • 11
  1. 1.Professor of Surgery and Oncology, Clinical Trials Group, Division of Surgery and Interventional ScienceUniversity College LondonLondonUK
  2. 2.Department of Clinical OncologyUniversity College London HospitalsLondonUK
  3. 3.Department of Radiation OncologyUniversity Medical Centre Mannheim, University of HeidelbergHeidelbergGermany
  4. 4.Department of SurgeryCentro di Riferimento OncologicoAvianoItaly
  5. 5.Department of BiostatisticsUniversity of Notre DameWAAustralia
  6. 6.School of SurgeryUniversity of Western AustraliaWAAustralia
  7. 7.Department of Breast SurgeryUniversity of CopenhagenCopenhagenDenmark
  8. 8.Department of SurgeryUniversity of CaliforniaCAUSA
  9. 9.Department of Gynecology and ObstetricsRed Cross HospitalMunichGermany
  10. 10.Department of Radiation OncologySir Charles Gairdner HospitalWAAustralia
  11. 11.Clinical Trials Group, Division of Surgery and Interventional ScienceUniversity College LondonLondonUK

Personalised recommendations